Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Haematopoetic stem cell transplantation
(HSCT) has revolutionized the treatment
of a wide range of haematological disorders. However, rejection and relapse remain a major complication after HSCT. This report discusses the potential for modern NGS-based methods to improve the management of patients after HSCT.
Haematopoetic stem cell transplantation
(HSCT) has revolutionized the treatment
of a wide range of haematological disorders. However, rejection and relapse remain a major complication after HSCT. This report discusses the potential for modern NGS-based methods to improve the management of patients after HSCT.
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
QF PCR analysis includes amplification, detection and analysis of chromosome-specific DNA sequences...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
A short tandem repeat (STR or microsatellite) is a pattern of two or more nucleotides that are...
Read More